Nautilus Biotechnology added Baylor College of Medicine as the first participant in its Iterative Mapping Early Access Program, providing access to the Voyager single‑molecule proteomics platform for isoform‑resolved studies of cancer proteoforms. Baylor investigators, funded by the NIH, will pair Voyager full‑length proteoform measurements with computational toolkits to cross‑compare transcriptional and proteomic isoform detection. Nautilus’s platform—integrating dense nano‑arrays, imaging, ML and reagents—aims to detect intact proteins and proteoforms not accessible to conventional shotgun proteomics. Early access placements and field tests at research centers underscore demand for high‑resolution protein mapping to improve target identification and biomarker discovery in oncology.